We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development

News   Nov 11, 2009

 
Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
 
 
 

RELATED ARTICLES

Curing Drug-Resistant Infections Without Antibiotics

News

Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.

READ MORE

Proactive Approach Protects Population From HIV

News

A preventative approach to HIV drastically reduced the number of HIV diagnoses in New South Wales, Australia.

READ MORE

Treatment Eliminates Nicotine Addiction in Preclinical Tests

News

Scientists at Scripps Research have successfully tested a potential new smoking-cessation treatment in rodents.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE